REFRACTORY THYROID GLAND CARCINOMA
Clinical trials for REFRACTORY THYROID GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY THYROID GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY THYROID GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Hard-to-Treat thyroid cancer
Disease control OngoingThis phase II trial tests a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—in 11 patients with advanced thyroid cancer that no longer responds to radioactive iodine or prior targeted therapy. The goal is to see if this mix can shrink tumors or stop them from g…
Matched conditions: REFRACTORY THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Precision drug tipifarnib targets rare HRAS cancers in kids
Disease control OngoingThis study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancers have a specific change in the HRAS gene. The cancers are advanced or have come back after treatment. The goal is to see if tipifarnib can shrink tumors or stop them from growing. A…
Matched conditions: REFRACTORY THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo offers hope for hard-to-treat thyroid cancer
Disease control OngoingThis study tests whether two targeted drugs (encorafenib and binimetinib) with or without an immunotherapy drug (nivolumab) can shrink or slow advanced thyroid cancer that has spread and no longer responds to standard radioactive iodine treatment. About 24 adults with a specific …
Matched conditions: REFRACTORY THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Can a cancer drug make radioactive iodine work again for thyroid tumors?
Disease control OngoingThis phase 2 trial tests whether the targeted drug trametinib can help radioactive iodine (I-131) work better in people with advanced thyroid cancer that has returned or spread. The study includes 34 participants whose cancer no longer responds to standard radioactive iodine trea…
Matched conditions: REFRACTORY THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC